DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.
前收盘价
US$9.02
−US$0.40 · -4.25%
盘中时间采用ET。市场数据可能有所延迟。
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.
日内区间
当前US$9.02
52周区间
当前US$9.02
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
15
估值过高
情绪
44
多空交织
风险
56
风险偏高
动量
34
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.
日内区间
当前US$9.02
52周区间
当前US$9.02
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | 1572.8万 USD | 484.4万 USD | 570.8万 USD |
| 销货成本 | — | 681.39万 USD | — | — | 1039.1万 USD |
| 毛利 | — | −681.39万 USD | 1572.8万 USD | 484.4万 USD | −468.3万 USD |
| 研究与开发 | 1.17亿 USD | 8990.19万 USD | 6022.3万 USD | 7554.3万 USD | 7033.6万 USD |
| 销售、一般及管理费用 | 3601万 USD | 2381.09万 USD | 3193.8万 USD | 2593.2万 USD | 2382.7万 USD |
| 营业费用 | 1.47亿 USD | 1.14亿 USD | 9216万 USD | 1.01亿 USD | 9393.1万 USD |
| 利息收入 | 60.1万 USD | 272.6万 USD | 371.4万 USD | 42.7万 USD | 52.1万 USD |
| 利息支出 | — | — | — | — | 69万 USD |
| 折旧和摊销 | 319.4万 USD | 681.39万 USD | 1316.2万 USD | 1316.2万 USD | 837.6万 USD |
| 营业利润 | −1.47亿 USD | −1.21亿 USD | −7643.2万 USD | −9663.1万 USD | −9861.4万 USD |
| 净利润 | −1.47亿 USD | −1.14亿 USD | −7272.6万 USD | −9627.4万 USD | −9780.9万 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$46.33
上涨空间 413.64%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年11月29日 | 1:5 | — | — |
股票拆分 | 2024年6月7日 | 1:2 | — | — |
已生效 2024年11月29日
1:5
已生效 2024年6月7日
1:2
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。